

# INVASIVE PNEUMOCOCCAL DISEASE IN AUSTRALIA, 2009 AND 2010

Christina Bareja, Cindy Toms, Kerryn Lodo, Rachel de Kluyver and the Enhanced Invasive Pneumococcal Disease Surveillance Working Group

## Abstract

Enhanced surveillance for invasive pneumococcal disease (IPD) was conducted in all Australian states and territories in 2009 and 2010 with comprehensive comparative data available since 2002. There were 1,556 cases of IPD notified to the National Notifiable Diseases Surveillance System in Australia in 2009, a notification rate of 7.2 cases per 100,000 population. In 2010 there were 1,640 cases, a notification rate of 7.4 cases per 100,000. The overall rate of IPD in Indigenous Australians was almost 6 times the rate in non-Indigenous Australians in both 2009 and 2010. In 2009 and 2010, notification rates of IPD caused by serotypes included in the 7-valent pneumococcal conjugate vaccine (7vPCV) continued to decrease across all age groups. Rates of IPD caused by non-7vPCV serotypes continued to show an increasing trend in both Indigenous and non-Indigenous children aged less than 5 years. In Indigenous adults ( $\geq 50$  years), rates of IPD caused by both 23-valent pneumococcal polysaccharide vaccine (23vPPV) serotypes and non-23vPPV serotypes continued to show an overall increase, particularly in 2010. There were 110 deaths attributed to IPD in 2009 and 137 in 2010, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remained low and reduced susceptibility to third generation cephalosporins was rare. *Commun Dis Intell* 2015;39(2):E265–E279.

Keywords: Australia, invasive pneumococcal disease, communicable disease surveillance, epidemiology, annual report

## Introduction

*Streptococcus pneumoniae* infection is a major cause of vaccine preventable disease worldwide.<sup>1,2</sup> The organism colonises the nasopharynx of healthy carriers who show no symptoms of disease. In susceptible groups, the bacterium can spread to the respiratory tract and sterile sites, such as the blood, cerebrospinal fluid or pleural fluid, and cause disease ranging from mild, such as otitis media and sinusitis, to more severe, such as pneumonia, septicaemia and meningitis.<sup>3</sup> The burden of disease is greatest in infants and the elderly. The 23-valent pneumococcal polysaccharide vaccine (23vPPV) was first recommended in Australia prior to 1991 for certain high risk groups. A 7-valent pneumococcal conju-

gate vaccine (7vPCV) program with a 3+0 schedule (i.e. 2, 4 and 6 month schedule without a conjugate vaccine booster) was first funded by the National Immunisation Program (NIP) for Aboriginal and Torres Strait Islander infants in mid-2001 with children in areas of very high incidence also funded for a 23vPPV booster at 18–24 months.<sup>4</sup> The 23vPPV is currently funded nationally for all individuals aged 65 years or over and Aboriginal and Torres Strait Islanders aged 50 years or over. From January 2005, NIP-funded 7vPCV was extended to all infants nationally, together with catch-up vaccination for all children aged less than 2 years. High vaccination uptake of over 90% has been maintained since the implementation of universal infant pneumococcal vaccination.<sup>4</sup> Enhanced surveillance of risk factors, invasive pneumococcal disease (IPD)-specific clinical details, microbiological and vaccination history is carried out for IPD, which has been nationally notifiable in Australia since 2001. Some states and territories hold data from earlier years. Surveillance reports have been published in *Communicable Diseases Intelligence* for 2002 to 2008.<sup>5–10</sup> This report describes epidemiological, microbiological and disease trends for the years 2009 and 2010.

## Methods

### Data collection

IPD is a nationally notifiable disease in Australia and is monitored using the National Notifiable Diseases Surveillance System (NNDSS). Complete data have been reported to the NNDSS from all states and territories since 2002. To varying degrees across jurisdictions, medical practitioners, public health laboratories and other health professionals are required under state and territory public health legislation to report cases of IPD to state and territory health authorities. The *National Health Security Act 2007* provides the legislative basis for the national notification of communicable diseases and authorises the exchange of health information between the Commonwealth and the states and territories.<sup>11</sup> Notified cases of IPD that meet the national surveillance case definition are transferred by state and territory health departments to the NNDSS regularly.<sup>12</sup> The primary responsibility for public health action resulting from notification resides with state and territory health departments.

The Communicable Diseases Network Australia (CDNA) established the Enhanced Invasive Pneumococcal Disease Surveillance Working Group (EIPDSWG) in 2000 to assist in the development and implementation of a nationally standardised approach to the enhanced surveillance of IPD in Australia. In 2009 and 2010, core organism and diagnosis data were collected for all notified cases, whereas enhanced data, which includes clinical categories and risk factors, were collected to varying degrees across states and territories (Table 1).

Data presented in this report represent a point in time analysis of notified cases of IPD. This report presents data extracted in July 2014 and analysed by date of diagnosis. Date of diagnosis is a derived field within the NNDSS and represents the onset date, or when the onset date was not known, the earliest of the specimen collection, notification, or notification receive dates. Due to the dynamic nature of the NNDSS, data in this report may vary from data reported in other NNDSS reports and reports of IPD notifications at the state or territory level.

Australian Bureau of Statistics mid-year estimated resident populations were used to calculate notification rates.<sup>13</sup>

### Case definition

Cases of IPD were notified according to the CDNA case definition for IPD.<sup>14</sup> A confirmed case requires definitive evidence only. Laboratory definitive evidence for IPD is the isolation from or detection by nucleic acid amplification test of *S. pneumoniae* in blood, cerebrospinal fluid or other sterile site.

### Indigenous status

Cases of IPD were reported indicating the Indigenous status of the individual. The definition of an Aboriginal or Torres Strait Islander within the NNDSS aligns with the Commonwealth definition, that is, an Aboriginal or Torres Strait Islander is determined by descent, self-identification and community acceptance.

Cases reported with an unknown Indigenous status (2009:195/1,556, 13%; 2010: 193/1,640, 12%)

were excluded from the analyses in this report relating to Indigenous status.

### Vaccination

Pneumococcal vaccination for various specified age groups and other high risk populations has been recommended within Australia since before 1991. In 2009–2010, primary pneumococcal vaccination and specified boosters were recommended and funded under the NIP for the following groups:

- all infants;
- children aged under 10 years with specified underlying medical conditions;
- Aboriginal and Torres Strait Islander children aged 18–24 months and living in high risk areas;
- Aboriginal and Torres Strait Islander people aged 15–50 years with specified underlying medical conditions;
- all Aboriginal and Torres Strait Islander people aged 50 years or over; and
- all adults aged 65 years or over.

NIP pneumococcal vaccination schedules for these groups were unchanged from those used in 2008.<sup>10</sup> From October 2009, the 10-valent pneumococcal conjugate vaccine (10vPCV) was funded as a replacement to the 7vPCV in the Northern Territory for all children. However, in this report, Northern Territory cases were not analysed separately. There are now 4 vaccines available in Australia with each targeting multiple serotypes (Table 2); however, the 13-valent pneumococcal conjugate vaccine (13vPCV) was not yet introduced to the Australian NIP during the years of this study, 2009 and 2010.

More information on the scheduling of the pneumococcal vaccination can be found on the [Immunise Australia web site](http://www.immunise.health.gov.au) (www.immunise.health.gov.au). A detailed history on vaccination recommendations and practices is available through the National Centre for Immunisation Research and Surveillance (NCIRS).<sup>15</sup>

The evaluation of vaccination status in this report is described in Table 3. These definitions are applied to the vaccination fields reported to the NNDSS and are agreed to by the EIPDSWG.

**Table 1: Enhanced invasive pneumococcal disease surveillance data collection performed by states and territories in 2009 and 2010**

| Age group     | State or territory  |
|---------------|---|
| Under 5 years | New South Wales, Queensland (Metro South and Gold Coast Public Health Units only).  |
| Over 50 years | New South Wales.  |
| All ages      | Australian Capital Territory, Northern Territory, Queensland (except Metro South and Gold Coast Public Health Units), Tasmania, South Australia, Victoria, Western Australia. |

**Table 2: Serotypes targeted by pneumococcal vaccines**

| Vaccine type   | Serotypes targeted by the vaccine   |
|--|---|
| 7-valent pneumococcal conjugate vaccine (7vPCV)        | 4, 6B, 9V, 14, 18C, 19F and 23F.  |
| 10-valent pneumococcal conjugate vaccine (10vPCV)      | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.  |
| 13-valent pneumococcal conjugate vaccine (13vPCV)      | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.  |
| 23-valent pneumococcal polysaccharide vaccine (23vPPV) | 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F. |

**Table 3: Definitions of vaccination status and vaccine failure used in this report**


| Category               | Definition   |
|------------------------|--|
| Fully vaccinated       | Those who have completed the primary course of the relevant vaccine(s) required for their age according to the most recent edition of <i>The Australian Immunisation Handbook</i> , at least 2 weeks prior to disease onset with at least 28 days between doses of vaccine.<br><br>This includes the following; <ul style="list-style-type: none"> <li>a child who received a vaccine as ‘catch up’ and therefore did not require a full 3 dose primary schedule. Providing they have had the number of doses required for the age they were at first dose they should be considered fully vaccinated.</li> </ul> NB: A young child who has had all the required doses for their age but is not old enough to have completed the primary course would not be assessed as fully vaccinated. |
| Vaccination validation | Written confirmation of vaccination through the Australian Childhood Immunisation Register, state or territory immunisation register or health record.   |
| Vaccine failure        | A fully vaccinated child (as defined above) with disease due to a serotype found in the corresponding vaccine.   |

**Results**

**Invasive pneumococcal disease notifications**

There were 1,640 cases of IPD notified in 2010, representing an annual notification rate of 7.4 per 100,000 population. This was a 5% increase on the 1,556 cases reported in 2009 (7.2 per 100,000). The number of cases of IPD notified to the NNDSS has been stable since 2005, when the universal pneumococcal conjugate vaccine program for young children was introduced (Figure 1).

**Figure 1: Notification and notification rate for invasive pneumococcal disease, Australia, 2002 to 2010**



A summary of the number and rates of notifications by jurisdiction is shown in Table 4. As in previous years, New South Wales accounted for the largest number of cases notified by a state or territory in 2009 (n=478) and 2010 (n=499) and the Northern Territory reported the highest notification rate in both 2009 (38.5 per 100,000) and 2010 (24.4 per 100,000). The Australian Capital Territory reported the smallest number of cases in both 2009 (n=30) and 2010 (n=25) and Queensland recorded the lowest notification rate in both 2009 (6.0 per 100,000) and 2010 (6.2 per 100,000).

The number of cases of IPD was greatest in the winter months with the peak number of notifications for both 2009 (n=226) and 2010 (n=218) occurring in July. The effect of season was more evident in the distribution of cases aged 5 years or over compared with younger children (Figure 2).

**Invasive pneumococcal disease by age and sex**


In almost all age groups, there was a greater notification rate of IPD in males than females. Consistent with 2007–2008, the highest rates in 2009 and 2010 combined were again among the elderly aged 85 years or over (34.4 per 100,000) and in children aged 1 year (30.8 per 100,000) (Figure 3).

**Table 4: Notified cases and notification rate for invasive pneumococcal disease, Australia, 2009 and 2010 by state or territory, age group and Indigenous status**


| Age and Indigenous status              | State or territory |     |      |     |      |      |      |      | Aust. |
|--|--------------------|-----|------|-----|------|------|------|------|-------|
|  | ACT                | NSW | NT   | Qld | SA   | Tas. | Vic. | WA   |       |
| <b>2009</b>                            |                    |     |      |     |      |      |      |      |       |
| <b>Notified cases aged &lt;5 years</b> |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 0                  | 3   | 16   | 3   | 0    | 0    | 0    | 4    | 26    |
| Non-Indigenous                         | 7                  | 70  | 3    | 37  | 21   | 1    | 40   | 26   | 205   |
| Total*                                 | 7                  | 73  | 19   | 55  | 21   | 1    | 45   | 30   | 251   |
| <b>Notified cases aged 5–64 years</b>  |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 1                  | 5   | 57   | 27  | 12   | 3    | 8    | 29   | 142   |
| Non-Indigenous                         | 16                 | 138 | 4    | 102 | 55   | 25   | 157  | 56   | 553   |
| Total*                                 | 17                 | 225 | 61   | 145 | 68   | 28   | 196  | 85   | 825   |
| <b>Notified cases ≥ 65 years</b>       |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 0                  | 2   | 5    | 3   | 1    | 0    | 0    | 1    | 12    |
| Non-Indigenous                         | 6                  | 178 | 2    | 39  | 55   | 9    | 102  | 33   | 424   |
| Total*                                 | 6                  | 180 | 7    | 59  | 56   | 10   | 128  | 34   | 480   |
| <b>Total</b>                           |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 1                  | 10  | 78   | 33  | 13   | 3    | 8    | 34   | 180   |
| Non-Indigenous                         | 29                 | 386 | 9    | 178 | 131  | 35   | 299  | 115  | 1,182 |
| Total*                                 | 30                 | 478 | 87   | 259 | 145  | 39   | 369  | 149  | 1,556 |
| Rate (per 100,000 population)          | 8.5                | 6.8 | 38.5 | 6.0 | 9.0  | 7.7  | 6.9  | 6.7  | 7.2   |
| Indigenous status completeness         | 100%               | 83% | 100% | 81% | 99%  | 97%  | 83%  | 100% | 87%   |
| <b>2010</b>                            |                    |     |      |     |      |      |      |      |       |
| <b>Notified cases aged &lt;5 years</b> |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 0                  | 4   | 10   | 6   | 2    | 0    | 1    | 14   | 37    |
| Non-Indigenous                         | 5                  | 91  | 2    | 32  | 22   | 4    | 47   | 32   | 235   |
| Total*                                 | 5                  | 95  | 12   | 42  | 24   | 4    | 58   | 46   | 286   |
| <b>Notified cases aged 5–64 years</b>  |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 2                  | 9   | 32   | 29  | 16   | 1    | 7    | 52   | 148   |
| Non-Indigenous                         | 14                 | 124 | 9    | 115 | 58   | 18   | 183  | 63   | 584   |
| Total*                                 | 16                 | 224 | 41   | 164 | 74   | 19   | 216  | 115  | 869   |
| <b>Notified cases ≥ 65 years</b>       |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 0                  | 4   | 2    | 2   | 0    | 0    | 0    | 3    | 11    |
| Non-Indigenous                         | 4                  | 176 | 1    | 44  | 41   | 23   | 109  | 34   | 432   |
| Total*                                 | 4                  | 180 | 3    | 65  | 41   | 23   | 132  | 37   | 485   |
| <b>Total</b>                           |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 2                  | 17  | 44   | 37  | 18   | 1    | 8    | 69   | 196   |
| Non-Indigenous                         | 23                 | 391 | 12   | 191 | 121  | 45   | 339  | 129  | 1,251 |
| Total*                                 | 25                 | 499 | 56   | 271 | 139  | 46   | 406  | 198  | 1,640 |
| Rate (per 100,000 population)          | 6.9                | 7.0 | 24.4 | 6.2 | 8.5  | 9.0  | 7.4  | 8.6  | 7.4   |
| Indigenous status completeness         | 100%               | 82% | 100% | 84% | 100% | 100% | 85%  | 100% | 88%   |

\* Total includes cases reported with a not stated or not reported Indigenous status.

**Figure 2: Notifications of invasive pneumococcal disease, Australia, 2009 and 2010, by month and year of diagnosis and age group**



**Figure 3: Notification rate for invasive pneumococcal disease, Australia, 2009 and 2010, by age group and sex**



In 2009, the rate of IPD in children aged under 2 years was 25.4 per 100,000 (Figure 4). In 2010, the rate in this age group increased to 30.5 per 100,000; however, overall the rate maintains the large decrease experienced in this age group as a result of the introduction of the universal 7vPCV immunisation program in 2005. Prior to the vaccination program the notification rate in this age group was close to 100 cases per 100,000 (Figure 4).


The overall rate of IPD in adults aged 65 years or over continued to slowly decline in 2009 (16.6 per 100,000) and 2010 (16.2 per 100,000).

**Invasive pneumococcal disease in Aboriginal and Torres Strait Islander people**

Indigenous status was reported in 87% of notifications in 2009 and in 88% of notifications in 2010 (Table 4). In 2009, there were 180 cases of IPD reported as Indigenous (11.6% of all cases). This

represents a rate of 33 cases per 100,000; a rate almost 6 times that seen in the non-Indigenous population (6.0 per 100,000). The rate of IPD among Indigenous people in 2010 was similar to 2009 with 196 cases representing 12.0% of all cases. Further analyses of the Indigenous population group are provided throughout this report.


**Figure 4: Notification rate for invasive pneumococcal disease, Australia, 2002 to 2010, by age group**



**Invasive pneumococcal disease in children**

The rate of IPD in Indigenous children aged less than 5 years in 2009 was 38.5 cases per 100,000 (n=26) and in 2010 was 53.5 cases per 100,000 (n=37) (Figure 5). The rate of IPD in non-Indigenous children aged less than 5 years in 2009 was 15.1 cases per 100,000 (n=205) and in 2010 was 17.0 cases per 100,000 (n=235).

**Figure 5: Notification rate for invasive pneumococcal disease in children aged less than 5 years, Australia, 2002 to 2010, by Indigenous status**




Data point labels represent the number of notifications.

The rate of IPD in Indigenous children aged:

- less than 12 months was 35 cases per 100,000 (n=5) in 2009 and 89 cases per 100,000 in 2010 (n=13) (Figure 6a);
- 12 to 23 months was 65 cases per 100,000 (n=9) in 2009 and 64 cases per 100,000 in 2010 (n=9); and
- 24 months to less than 60 months was 30 cases per 100,000 (n=12) in 2009 and 37 cases per 100,000 in 2010 (n=15).

**Figure 6a: Notification rate for invasive pneumococcal disease in Indigenous children aged less than 5 years, Australia, 2002 to 2010, by Indigenous status and age group**




Simple average of data from 2002 to 2004.

The rate of IPD in Indigenous children fluctuated over the period due to the small number of notifications.

Less variability was seen in non-Indigenous children. Despite a slight increase in the rate of IPD in non-Indigenous children between 2009 and 2010, there has been an overall decrease in the rate since the implementation of the universal 7vPCV immunisation program in 2005. The IPD rate in non-Indigenous children aged:

- less than 12 months was 20 cases per 100,000 (n=54) in 2009 and 22 cases per 100,000 in 2010 (n=61) (Figure 6b);
- 12 to 23 months was 21 cases per 100,000 (n=57) in 2009 and 26 cases per 100,000 in 2010 (n=73); and
- 24 to less than 60 months was 10 cases per 100,000 (n=82) in 2009 and 11 cases per 100,000 in 2010 (n=87).

**Figure 6b: Notification rate for invasive pneumococcal disease in non-Indigenous children aged less than 5 years, Australia, 2002 to 2010, by Indigenous status and age group**



Simple average of data from 2002 to 2004.

### Mortality of invasive pneumococcal disease cases

Mortality data were reported for 63% (n=987) of IPD cases notified in 2009 and 62% (n=1,013) in 2010 (Table 5). One hundred and ten and 137 deaths associated with IPD were reported in 2009 and 2010, respectively.

Overall, case fatality rates (CFR) in notifications reported as non-Indigenous were higher than in those reported as Indigenous. In 2009, death associated with IPD was reported in 9 Indigenous cases (CFR=5.0%) and in 96 non-Indigenous cases (CFR=8.1%). In 2010, death associated with IPD was reported in 10 Indigenous cases (CFR=5.1%) and in 122 non-Indigenous cases (CFR=9.8%).

In those aged less than 5 years, there were 3 deaths associated with IPD in 2009 and 10 deaths in 2010 giving case fatality rates of 1.2% and 3.5% respectively. Three of the deaths that occurred in 2010 were in cases reported as Indigenous children. Further details, including serotype and vaccination history, of the 13 children aged less than 5 years whose deaths were associated with IPD are shown in Table 6.

### Risk factors for invasive pneumococcal disease

Risk factor data were provided for 69% (2,221/3,196) of cases reported in 2009 and 2010. Of the cases with risk factor data reported, 76% (1,696) of cases reported at least 1 risk factor and 11% (243) of cases reported that no risk factors were identified.

**Table 5: Deaths and case fatality rates\* for invasive pneumococcal disease, Australia, 2009 and 2010, by age group, Indigenous status and state or territory**

| Age group                              | State or territory |     |      |     |      |      |      |      | Aust. |
|--|--------------------|-----|------|-----|------|------|------|------|-------|
|  | ACT                | NSW | NT   | Qld | SA   | Tas. | Vic. | WA   |       |
| <b>2009</b>                            |                    |     |      |     |      |      |      |      |       |
| <b>Notified cases aged &lt;5 years</b> |                    |     |      |     |      |      |      |      |       |
| Deaths                                 | 0                  | 0   | 1    | 1   | 0    | 0    | 1    | 0    | 3     |
| Case fatality rate*                    | 0.0                | N/A | 5.3  | 1.8 | N/A  | 0.0  | 2.2  | 0.0  | 1.2   |
| <b>Notified cases aged 5–64 years</b>  |                    |     |      |     |      |      |      |      |       |
| Deaths                                 | 0                  | 12  | 2    | 8   | 2    | 1    | 11   | 4    | 40    |
| Case fatality rate*                    | 0.0                | N/A | 3.3  | 5.5 | 2.9  | 3.6  | 5.6  | 4.7  | 4.8   |
| <b>Notified cases ≥ 65 years</b>       |                    |     |      |     |      |      |      |      |       |
| Deaths                                 | 0                  | 41  | 1    | 3   | 3    | 3    | 12   | 4    | 67    |
| Case fatality rate*                    | 0.0                | N/A | 14.3 | N/A | 5.4  | 30.0 | 9.4  | 11.8 | 14.0  |
| <b>Total</b>                           |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 0                  | 0   | 4    | 2   | 1    | 0    | 0    | 2    | 9     |
| Non-Indigenous                         | 0                  | 53  | 0    | 10  | 4    | 4    | 19   | 6    | 96    |
| Total†                                 | 0                  | 53  | 4    | 12  | 5    | 4    | 24   | 8    | 110   |
| Death reporting completeness (%)       | 100                | 11  | 100  | 54  | 87   | 100  | 98   | 100  | 63    |
| <b>2010</b>                            |                    |     |      |     |      |      |      |      |       |
| <b>Notified cases aged &lt;5 years</b> |                    |     |      |     |      |      |      |      |       |
| Deaths                                 | 0                  | 1   | 0    | 2   | 1    | 0    | 1    | 5    | 10    |
| Case fatality rate*                    | 0.0                | N/A | 0.0  | N/A | 4.2  | 0.0  | 1.7  | 10.9 | 3.5   |
| <b>Notified cases aged 5–64 years</b>  |                    |     |      |     |      |      |      |      |       |
| Deaths                                 | 0                  | 14  | 1    | 6   | 3    | 1    | 10   | 6    | 41    |
| Case fatality rate*                    | 0.0                | N/A | 2.4  | N/A | 4.1  | 5.3  | 4.6  | 5.2  | 4.7   |
| <b>Notified cases ≥ 65 years</b>       |                    |     |      |     |      |      |      |      |       |
| Deaths                                 | 2                  | 40  | 1    | 1   | 5    | 7    | 22   | 8    | 86    |
| Case fatality rate*                    | 50.0               | N/A | 33.3 | N/A | 12.2 | 30.4 | 16.7 | 21.6 | 17.7  |
| <b>Total</b>                           |                    |     |      |     |      |      |      |      |       |
| Indigenous                             | 0                  | 1   | 2    | 1   | 0    | 0    | 1    | 5    | 10    |
| Non-Indigenous                         | 2                  | 54  | 0    | 8   | 9    | 8    | 27   | 14   | 122   |
| Total†                                 | 2                  | 55  | 2    | 9   | 9    | 8    | 33   | 19   | 137   |
| Death reporting completeness (%)       | 100                | 11  | 100  | 32  | 100  | 100  | 100  | 100  | 62    |

\* Jurisdictional specific case fatality rates have not been presented for those jurisdictions where completeness of data was less than 50%; denoted as 'N/A'. Rates shown should be interpreted with caution given the proportion of cases without mortality data reported to the NNDSS, as well as the variability across jurisdictions in reporting death as primary and secondary causes.

† All notified cases include cases reported with a not stated or not reported Indigenous status.

Table 7 shows data on the risk factors for IPD in specified population sub-groups for 2009 and 2010 combined.

In children aged less than 5 years, the most frequently reported risk factor in the Indigenous population was premature birth (< 37 weeks gestation, 25% of cases with a risk factor reported), while childcare attendance was the most fre-

quently reported risk factor in the non-Indigenous population (35% of cases with risk factor data reported). Among the adult population groups, Indigenous cases aged greater than 50 years and non-Indigenous cases aged greater than 65 years, chronic illness was the most frequently reported risk factor, with 46% and 41% of cases with a risk factor reported respectively.

**Table 6: Characteristics of deaths from invasive pneumococcal disease in children aged less than 5 years of age, Australia, 2009 and 2010**

| Case   | Year of diagnosis | Sex    | Age (months) | Indigenous status | Serotype    | Doses of 7vPCV | Risk factors  |
|--|-------------------|--------|--------------|-------------------|-------------|----------------|---|
| <b>Deaths potentially preventable by 7vPCV</b> |                   |        |              |                   |             |                |   |
| 1  | 2009              | Male   | 16           | Non-Indigenous    | 19F         | 3              | Other*  |
| <b>Deaths not preventable by 7vPCV</b>         |                   |        |              |                   |             |                |   |
| 2  | 2009              | Male   | 10           | Indigenous        | 16F         | 2              | Chronic illness and other   |
| 3  | 2009              | Female | 16           | Non-Indigenous    | 8           | 0              | Unknown   |
| 4  | 2010              | Male   | 5            | Indigenous        | 1           | 1              | Anatomic or functional asplenia   |
| 5  | 2010              | Female | 55           | Non-Indigenous    | 11A         | 0              | Unknown   |
| 6  | 2010              | Female | 10           | Non-Indigenous    | 18A         | 3              | Unknown   |
| 7  | 2010              | Female | 6            | Non-Indigenous    | 19A         | 3              | No risk factor identified   |
| 8  | 2010              | Male   | 12           | Non-Indigenous    | 19A         | 3              | Information not supplied  |
| 9  | 2010              | Male   | 1            | Non-Indigenous    | 23B         | 0              | No risk factor identified   |
| 10   | 2010              | Female | 1            | Non-Indigenous    | 35B         | 0              | No risk factor identified   |
| 11   | 2010              | Male   | 2            | Non-Indigenous    | 7F          | 0              | Premature (<37 weeks gestation) and Congenital or chromosomal abnormality |
| 12   | 2010              | Male   | 23           | Non-Indigenous    | Non-typable | 3              | Unknown   |
| 13   | 2010              | Female | 3            | Indigenous        | Untyped     | 1              | No risk factor identified   |

\* Other risk factors include but are not limited to exposure to smoke, asthma and previous pneumonia.

Mortality caveat:

NNDSS is generally a passive surveillance system that contains a minimum dataset including whether or not the case 'died of the notifiable condition'. The specific manner in which these data items are collected has not been standardised and therefore varies from jurisdiction to jurisdiction. There is consensus that data reported here includes deaths within the first one to two weeks of diagnosis.

**Table 7: Numbers of risk factors\* for invasive pneumococcal disease population sub-groups, Australia, 2009 and 2010**

| Risk factor                           | Children aged less than 5 years |                | Indigenous aged 50 years or over | Non-Indigenous aged 65 years or over |
|---------------------------------------|---------------------------------|----------------|----------------------------------|--------------------------------------|
|                                       | Indigenous                      | Non-Indigenous |                                  |                                      |
| Premature (<37 weeks gestation)       | 14                              | 29             | N/A                              | N/A                                  |
| Congenital or chromosomal abnormality | 5                               | 14             | 1                                | 0                                    |
| Anatomic or functional asplenia       | 1                               | 1              | 2                                | 12                                   |
| Immunocompromised                     | 3                               | 18             | 14                               | 203                                  |
| Chronic illness                       | 7                               | 14             | 56                               | 386                                  |
| Childcare attendee                    | 4                               | 61             | N/A                              | N/A                                  |
| Previous episode of IPD               | 2                               | 1              | 5                                | 7                                    |
| Other†                                | 21                              | 34             | 43                               | 344                                  |
| No risk factor identified             | 14                              | 88             | 3                                | 29                                   |
| Unknown or not reported               | 14                              | 217            | 13                               | 186                                  |
| Total                                 | 63                              | 440            | 81                               | 856                                  |

\* Case may be reported with more than one risk factor.

† Other risk factors include but are not limited to exposure to smoke, asthma and previous pneumonia.

N/A Not applicable.

**Pneumococcal serotypes causing invasive disease**

While serotype information does not influence initial clinical care, it is necessary to monitor the effectiveness of vaccination programs and inform future policy. It is also recognised that specific serotypes may be associated with certain disease presentation and severity and may have identifiable antibiotic susceptibility patterns. Pneumococcal serotypes were identified for 95% (1,483/1,556) of all notified cases in 2009 and for 94% (1,546/1,640) in 2010.

Of all the cases reported with a serotype in 2009 and 2010, 12% (370/3,029) were due to serotypes covered by the 7vPCV. This ranged from 2% (1/61) of Indigenous cases aged less than 5 years to 15% (81/554) of non-Indigenous cases aged 5–49 years. The 3 additional serotypes (1, 5 and 7F) covered by the 10vPCV accounted for an additional 10% (300/3,029) of cases in 2009 and 2010, which ranged from 3% (27/815) of non-Indigenous adults aged 65 years or over to 19% (103/554) of non-Indigenous cases aged 5–49 years. The 3 additional serotypes (3, 6A and 19A) covered by the 13vPCV accounted for an additional 34% (1,027/3,029) of cases, ranging from 9% (19/220) of Indigenous cases aged 5–49 years to 57% (234/409) of non-Indigenous cases aged less than 5 years.

There are an additional 16 serotypes covered by the 23vPPV, in addition to the seven covered by the 7vPCV. Of all the cases reported with a serotype in 2009 and 2010, 65% (1,982/3,029) of all cases were due to these additional 16 serotypes. This ranged from 53% (431/815) of non-Indigenous adults aged 65 years or over to 74% (303/409) of non-Indigenous cases aged less than 5 years.

Table 8 and the remainder of the analyses included in this section consider the number and proportions of IPD cases due to serotypes covered by the various pneumococcal vaccines and their target age groups. Note that 13vPCV is included in Table 8 pending its introduction to the NIP in 2011.


*7-valent pneumococcal conjugate vaccine serotypes*

Overall, the notification rate of IPD due to 7vPCV serotypes has continued to decrease across all age groups since 2002 (Figure 7). Since the 2005 introduction of the universal 7vPCV immunisation program, the notification rate of IPD in all age groups decreased by 78% in 2009 (4.5 to 1.0 per 100,000) and 84% in 2010 (4.5 to 0.7 per 100,000).


Figure 8 shows rates of IPD caused by 7vPCV serotypes in Indigenous and non-Indigenous children aged less than 5 years since 2002. The rate of IPD

due to 7vPCV serotypes in Indigenous children remained low in 2009 (0 per 100,000) and 2010 (1.4 per 100,000). Similarly, rates also remained low in non-Indigenous children in 2009 (1.1 per 100,000) and 2010 (0.9 per 100,000).

**Figure 7: Notification rate for invasive pneumococcal disease caused by 7vPCV serotypes, Australia, 2002 to 2010, by age group**



**Figure 8: Notification rate for 7vPCV and non-7vPCV serotypes causing cases of invasive pneumococcal disease in children aged less than 5 years, 2002 to 2010, by Indigenous status**



Simple average of data from 2002 to 2004.

|          | Indigenous |               | Non-Indigenous |               |
|----------|------------|---------------|----------------|---------------|
|          | 7vPCV (n)  | Non-7vPCV (n) | 7vPCV (n)      | Non-7vPCV (n) |
| 2002-04* | 17         | 22            | 470            | 66            |
| 2005     | 6          | 21            | 160            | 80            |
| 2006     | 4          | 21            | 61             | 95            |
| 2007     | 2          | 34            | 26             | 160           |
| 2008     | 5          | 32            | 22             | 180           |
| 2009     | 0          | 25            | 15             | 178           |
| 2010     | 1          | 35            | 12             | 204           |

**Table 8: Notified cases of invasive pneumococcal disease, Australia, 2009 and 2010, by pneumococcal vaccine serotypes**

| Age group   | Vaccine type                    | Indigenous |     |                | Non-Indigenous |     |                |
|-------------|---------------------------------|------------|-----|----------------|----------------|-----|----------------|
|             |                                 | Number     | %   | Cumulative (%) | Number         | %   | Cumulative (%) |
| <5 years    | 7vPCV                           | 1          | 2   | 2              | 27             | 7   | 7              |
|             | 10vPCV (non-7vPCV)              | 11         | 18  | 20             | 25             | 6   | 13             |
|             | 13vPCV (non-10vPCV)             | 15         | 25  | 44             | 234            | 57  | 70             |
|             | Non-conjugate vaccine serotypes | 34         | 56  | 100            | 123            | 30  | 100            |
|             | Total                           | 61         | 100 |                | 409            | 100 |                |
|             | 23vPPV (non-7vPCV)              | 45         | 74  |                | 303            | 74  |                |
| 5–49 years  | 7vPCV                           | 17         | 8   | 8              | 81             | 15  | 15             |
|             | 10vPCV (non-7vPCV)              | 34         | 15  | 23             | 103            | 19  | 33             |
|             | 13vPCV (non-10vPCV)             | 19         | 9   | 32             | 161            | 29  | 62             |
|             | Non-conjugate vaccine serotypes | 150        | 68  | 100            | 209            | 38  | 100            |
|             | Total                           | 220        | 100 |                | 554            | 100 |                |
|             | 23vPPV (non-7vPCV)              | 140        | 64  |                | 366            | 66  |                |
| 50–64 years | 7vPCV                           | 3          | 5   | 5              | 76             | 14  | 14             |
|             | 10vPCV (non-7vPCV)              | 8          | 14  | 19             | 47             | 9   | 23             |
|             | 13vPCV (non-10vPCV)             | 11         | 19  | 39             | 181            | 34  | 57             |
|             | Non-conjugate vaccine serotypes | 35         | 61  | 100            | 227            | 43  | 100            |
|             | Total                           | 57         | 100 |                | 531            | 100 |                |
|             | 23vPPV (non-7vPCV)              | 37         | 65  |                | 342            | 64  |                |
| 65+ years   | 7vPCV                           | 1          | 5   | 5              | 112            | 14  | 14             |
|             | 10vPCV (non-7vPCV)              | 2          | 10  | 14             | 27             | 3   | 17             |
|             | 13vPCV (non-10vPCV)             | 4          | 19  | 33             | 268            | 33  | 50             |
|             | Non-conjugate vaccine serotypes | 14         | 67  | 100            | 408            | 50  | 100            |
|             | Total                           | 21         | 100 |                | 815            | 100 |                |
|             | 23vPPV (non-7vPCV)              | 12         | 57  |                | 431            | 53  |                |
| Total       | 7vPCV                           | 22         | 6   | 6              | 296            | 13  | 13             |
|             | 10vPCV (non-7vPCV)              | 55         | 15  | 21             | 202            | 9   | 22             |
|             | 13vPCV (non-10vPCV)             | 49         | 14  | 35             | 844            | 37  | 58             |
|             | Non-conjugate vaccine serotypes | 233        | 65  | 100            | 967            | 42  | 100            |
|             | Total                           | 359        | 100 |                | 2,309          | 100 |                |
|             | 23vPPV (non-7vPCV)              | 234        | 65  |                | 571            | 25  |                |

Notifications with Indigenous status and/or serotype reported as unknown are excluded.

Since 2002, the rate of IPD disease caused by non-7vPCV serotypes has increased overall for both Indigenous and non-Indigenous children aged less than 5 years. The rate of IPD due to non-7vPCV serotypes in Indigenous children was 37 per 100,000 in 2009 and 51 per 100,000 in 2010, and in non-Indigenous children was 13 per 100,000 in 2009 and 15 per 100,000 in 2010.

Increasing rates of invasive pneumococcal disease caused by serotypes not contained in the 7vPCV

has been observed since 2005 with serotypes 19A and 6A the more commonly occurring replacement serotypes. The number of cases due to serotype 19A has continued to show an overall increase since 2002 in both Indigenous and non-Indigenous children aged less than 5 years. The number of cases due to the 19A serotype in Indigenous children was four in 2009 and seven in 2010. The number of cases due to the 19A serotype in non-Indigenous children was 104 in 2009 and 108 in 2010. The number of cases due to serotype 6A has

remained steady in Indigenous children aged less than 5 years with two cases notified in 2009 and a single case notified in 2010. The number of cases due to the 6A serotype in non-Indigenous children was four in 2009 and two in 2010.

*23-valent pneumococcal polysaccharide vaccine serotypes*

Figure 9 shows rates of IPD caused by 23vPPV serotypes in the groups targeted to receive the vaccine including Indigenous adults aged 50 years or over and non-Indigenous adults aged 65 years or over. In Indigenous adults, the rate of disease caused by 23vPPV serotypes continued to show an overall increase with a rate of 29 per 100,000 in 2009 and 43 per 100,000 in 2010. Conversely, in non-Indigenous adults the rate continued to show a decreasing trend with a rate of 9.4 per 100,000 in 2009 and 8.8 per 100,000 in 2010.

The rate of disease caused by non-23vPPV serotypes continued to show an overall increase in both

Indigenous and non-Indigenous adults. The rate of IPD disease caused by non-23vPPV was 19 per 100,000 in both 2009 and 2010 for Indigenous adults and 4.7 per 100,000 in 2009 and 5.1 per 100,000 in 2010 for non-Indigenous adults.

The number of cases due to serotype 19A in Indigenous adults showed a slight overall increase since 2002 with 6 cases in 2009 and 4 cases in 2010. The number of cases due to serotype 19A in non-Indigenous adults showed a more marked increase since 2002 with 88 cases in 2009 and 78 cases in 2010. The number of cases due to serotype 6A has remained steady in Indigenous adults with 1 case in 2009 and no cases in 2010. The number of cases due to serotype 6A showed an overall increase from 2002 to 2008; however, have since decreased with 16 cases in 2009 and 12 cases in 2010.


**Vaccine failures**

In 2009 and 2010, a total of 17 children who were considered fully vaccinated, were notified with disease due to 7vPCV serotypes (Table 9). Sixteen of the 17 cases were reported as non-Indigenous and 1 case did not have Indigenous status identified. Serotype 19F was reported in 76% (n=13) of these cases.

**Antibiotic resistance**

Antimicrobial resistance in invasive pneumococci is an emerging problem in Australia.<sup>16</sup> Antibiotic susceptibility testing was performed across all jurisdictions by a range of different methods. Penicillin and ceftriaxone/cefotaxime susceptibility data were analysed only for jurisdictions that reported susceptibility data for more than 50% of cases. Penicillin susceptibility completeness was suitable for reporting for all jurisdictions in 2009 and all jurisdictions, excluding Victoria in 2010. Similarly, ceftriaxone/cefotaxime susceptibility completeness was suitable for reporting for all jurisdictions, in 2009 and for all jurisdictions, excluding Victoria in 2010.

**Figure 9: Notification rate for 23vPPV and non-23vPPV serotypes causing cases of invasive pneumococcal disease in Indigenous adults (aged 50 years or over) and non-Indigenous adults (aged 65 years or over), 2002 to 2010**



Simple average of data from 2002 to 2004.

|          | Indigenous |                | Non-Indigenous |                |
|----------|------------|----------------|----------------|----------------|
|          | 23vPPV (n) | Non-23vPPV (n) | 23vPPV (n)     | Non-23vPPV (n) |
| 2002-04* | 14         | 5              | 413            | 55             |
| 2005     | 15         | 11             | 393            | 47             |
| 2006     | 15         | 10             | 358            | 84             |
| 2007     | 19         | 6              | 322            | 92             |
| 2008     | 26         | 7              | 329            | 137            |
| 2009     | 20         | 13             | 269            | 134            |
| 2010     | 31         | 14             | 261            | 151            |

Throughout the report period, the proportion of isolates with reduced susceptibility to penicillin increased from 10% (2009: 133/1,306) to 16% (2010: 180/1,139) of total isolates tested, mainly due to a 50% increase in the number of isolates with intermediate susceptibility (Table 10). This compares with a steady rate of 11% for 2007 and 2008. Of the isolates in 2009 with reduced susceptibility to penicillin, 131 were serotyped, with 22% (29/131) of these cases due to a serotype in the 7vPCV and 85% (113/131) due to a serotype in the 23vPPV; in 2010, 176 were serotyped, with 18% (32/176) of these cases due to a serotype in the 7vPCV and 72% (130/180) due to a serotype in the 23vPPV.

**Table 9: Characteristics of 7vPCV vaccine failures in children aged less than 5 years, Australia, 2009 and 2010**

| Case | Year of diagnosis | Age (months) | Indigenous status | Serotype | Doses of 7vPCV | Clinical category | Risk factors |
|------|-------------------|--------------|-------------------|----------|----------------|-------------------|--------------|
| 1    | 2009              | 28           | Non-Indigenous    | 19F      | 3              | Bacteraemia       | Unknown      |
| 2    | 2009              | 31           | Non-Indigenous    | 19F      | 3              | Pneumonia         | Yes          |
| 3    | 2009              | 37           | Non-Indigenous    | 19F      | 3              | Bacteraemia       | Unknown      |
| 4    | 2009              | 58           | Not reported      | 14       | 3              | Pneumonia         | No           |
| 5    | 2009              | 16           | Non-Indigenous    | 19F      | 3              | Bacteraemia       | Yes          |
| 6    | 2009              | 30           | Non-Indigenous    | 19F      | 3              | Bacteraemia       | Unknown      |
| 7    | 2009              | 22           | Non-Indigenous    | 19F      | 3              | Bacteraemia       | Unknown      |
| 8    | 2009              | 43           | Non-Indigenous    | 23F      | 3              | Bacteraemia       | Yes          |
| 9    | 2009              | 51           | Non-Indigenous    | 18C      | 3              | Pneumonia         | Unknown      |
| 10   | 2010              | 13           | Non-Indigenous    | 23F      | 3              | Bacteraemia       | Unknown      |
| 11   | 2010              | 51           | Non-Indigenous    | 19F      | 3              | Meningitis        | Yes          |
| 12   | 2010              | 56           | Non-Indigenous    | 19F      | 3              | Pneumonia         | Unknown      |
| 13   | 2010              | 25           | Non-Indigenous    | 19F      | 3              | Pneumonia         | Yes          |
| 14   | 2010              | 34           | Non-Indigenous    | 19F      | 3              | Pneumonia         | Unknown      |
| 15   | 2010              | 45           | Non-Indigenous    | 19F      | 3              | Bacteraemia       | Unknown      |
| 16   | 2010              | 47           | Non-Indigenous    | 19F      | 3              | Pneumonia         | Unknown      |
| 17   | 2010              | 10           | Non-Indigenous    | 19F      | 3              | Pneumonia         | No           |

Of the isolates with reduced susceptibility to penicillin in 2009, 77 were serotype 19A, eight were 9V, and 11 were 19F, accounting for 72% (96/133) of isolates with reduced penicillin susceptibility and with a known serotype. Of the isolates with reduced susceptibility to penicillin in 2010, 110 were serotype 19A, three were 9V, and 13 were 19F, which together account for 70% (126/180) of isolates with reduced penicillin susceptibility and with a known serotype.

With respect to ceftriaxone/cefotaxime, the proportion of isolates with reduced susceptibility has remained consistent at 2% (2009: 21/1,090) to 3% (2010: 27/986). These results were similar to 2007 and 2008, which were 3% (25/834) and 2% (16/910) respectively. All of the isolates in 2009 with reduced susceptibility to ceftriaxone/cefotaxime were serotyped, with 29% (6/21) due to a serotype in the 7vPCV and 62% (13/21) to a serotype in the 23vPPV. Of the isolates in 2010 with reduced susceptibility to ceftriaxone/cefotaxime, 26 were serotyped, with 38% (10/26) due to a serotype in the 7vPCV and 69% (18/26) due to a serotype in the 23vPPV.

Of the isolates with reduced susceptibility to ceftriaxone/cefotaxime in 2009, 12 were serotype 19A, one was 9V, and five were 19F, accounting for 86% (18/21) of isolates with reduced ceftriaxone/cefotaxime susceptibility and with a known serotype. Of the isolates with reduced susceptibility to cef-

triaxone/cefotaxime in 2010, 15 were serotype 19A, one was 9V, and six were 19F, accounting for 85% (22/26) of isolates with reduced ceftriaxone/cefotaxime susceptibility and with a known serotype.

## Discussion

In 2009, 1,556 cases of IPD were notified in Australia compared with 1,640 in 2010. The overall rate of IPD in Australia has been stable since 2006, the first year following introduction of the universal 7vPCV program in children. During the study period, the highest notification rates were among adults aged 80 years or over (27 per 100,000) and among children under 5 years of age (19 per 100,000). However, small increases in notification rates across most age groups were observed in 2010.

The number of IPD notifications due to serotypes included in the 7vPCV has continued to decline since the introduction of the universal infant (3+0 schedule) vaccination program in 2005. Since 2005, the most marked reduction has been in children aged less than 5 years, where disease burden due to 7vPCV serotypes has declined by 97%. In contrast, notifications of disease due to non-7vPCV serotypes increased by 71% in this age group over the same period suggesting serotype replacement. Substantial impacts on IPD due to serotypes covered by vaccines in vaccinated age groups, herd immunity impacts on adults, as well as variable levels of serotype replacement have

**Table 10: *Streptococcus pneumoniae* susceptibility to penicillin and ceftriaxone/cefotaxime,\* for selected states and territories, 2009 and 2010**

|  | 9V      | 19F      | All 7vPCV serotypes | 19A       | All 23vPPV | Not specified | All isolates |
|--|---------|----------|---------------------|-----------|------------|---------------|--------------|
| <b>2009</b>                                    |         |          |                     |           |            |               |              |
| <b>Penicillin</b>                              |         |          |                     |           |            |               |              |
| Resistant                                      | 4       | 5        | 14                  | 14        | 29         | 1             | 36           |
| Intermediate                                   | 4       | 6        | 15                  | 63        | 84         | 1             | 97           |
| Sensitive                                      | 9       | 33       | 151                 | 230       | 861        | 40            | 1,173        |
| Total tested                                   | 17      | 44       | 180                 | 307       | 974        | 42            | 1,306        |
| Total isolates with reduced susceptibility (%) | 8 (47%) | 11 (25%) | 29 (16%)            | 77 (25%)  | 113 (12%)  | 2 (5%)        | 133 (10%)    |
| <b>Ceftriaxone</b>                             |         |          |                     |           |            |               |              |
| Resistant                                      | 0       | 2        | 2                   | 3         | 3          | 0             | 5            |
| Intermediate                                   | 1       | 3        | 4                   | 9         | 10         | 0             | 16           |
| Sensitive                                      | 11      | 34       | 142                 | 245       | 752        | 25            | 1,069        |
| Total tested                                   | 12      | 39       | 148                 | 257       | 765        | 25            | 1,090        |
| Total isolates with reduced susceptibility (%) | 1 (8%)  | 5 (13%)  | 6 (4%)              | 12 (5%)   | 13 (2%)    | 0 (0%)        | 21 (2%)      |
| <b>2010</b>                                    |         |          |                     |           |            |               |              |
| <b>Penicillin</b>                              |         |          |                     |           |            |               |              |
| Resistant                                      | 3       | 6        | 14                  | 13        | 18         | 1             | 29           |
| Intermediate                                   | 5       | 7        | 18                  | 97        | 112        | 3             | 151          |
| Sensitive                                      | 4       | 12       | 69                  | 164       | 653        | 38            | 959          |
| Total tested                                   | 12      | 25       | 101                 | 274       | 783        | 42            | 1,139        |
| Total isolates with reduced susceptibility (%) | 8 (67%) | 13 (52%) | 32 (32%)            | 110 (40%) | 130 (17%)  | 4 (10%)       | 180 (16%)    |
| <b>Ceftriaxone</b>                             |         |          |                     |           |            |               |              |
| Resistant                                      | 0       | 1        | 2                   | 3         | 4          | 0             | 5            |
| Intermediate                                   | 1       | 5        | 8                   | 12        | 14         | 1             | 22           |
| Sensitive                                      | 9       | 17       | 78                  | 216       | 667        | 25            | 959          |
| Total tested                                   | 10      | 23       | 88                  | 231       | 685        | 26            | 986          |
| Total isolates with reduced susceptibility (%) | 1 (10%) | 6 (26%)  | 10 (11%)            | 15 (6%)   | 18 (3%)    | 1 (4%)        | 27 (3%)      |

\* Susceptibility data are restricted to jurisdictions with completeness suitable for reporting (greater than 50% completeness). Penicillin and ceftriaxone/cefotaxime susceptibility completeness was suitable for reporting in both 2009 for all jurisdictions. However, penicillin and ceftriaxone/cefotaxime susceptibility completeness was not suitable for reporting in 2010 in Victoria.

also been seen in other countries with established 7vPCV programs including England, Wales and the United States of America.<sup>17, 18</sup>

During 2009–2010 the most prevalent serotypes reported to cause IPD were 19A, 22F, 3, 7F and 6C, which together accounted for almost half of all notifications. Across all age categories, increases in the number of IPD infections due to serotypes 19A and 22F in particular were noted.

For the 2009–2010 study period, the proportion of cases due to infection with serotype 6C (6.7% of cases for which information on serotype was

available) was a marked increase compared with 2008 (2.5%) and 2007 (1.9%). The majority of cases were in adults aged 65 years or over. The increased prevalence in nasopharyngeal carriage of serotype 6C after vaccination has been previously described in a study of seven cohorts of Massachusetts children between 1994 and 2007.<sup>19</sup> Currently, serotype 6C is not covered by any of the licensed vaccines. However, there is evidence that 13vPCV has the potential to confer cross-protection against serotypes not directly covered by the vaccine, namely serotypes 6C and 7A.<sup>20, 21</sup> These findings support the idea of introducing 13vPCV into national vaccination schemes.

Among the most prevalent serotypes, serotypes 19A (n=55) and 3 (n=22) accounted for the highest number of deaths. Serotype 19A has emerged worldwide to be an important serotype associated with IPD, pneumonia, acute otitis media, and haemolytic uremic syndrome.<sup>22,23</sup> It has been proposed that the high incidence of multidrug-resistant 19A provides it with an advantage over other serotypes through selective pressure.<sup>24</sup> Serotype 3 has been associated with more severe disease and increased mortality in other countries, but the mechanisms underlying this are currently unknown.<sup>25</sup> Serotype 6B isolates frequently exhibit resistance to antibiotics and accounted for the second highest serotype-specific fatality rate (23%) during the study period.<sup>26,27</sup> However, the relationship between antibiotic resistance and mortality has not been formally evaluated. In Australia, analysis of serotype-specific fatality rates should be interpreted with caution due to the small number of cases for which serotype and death are known (n=214).

One of the major objectives of IPD surveillance is in assessment of serotype replacement, which is defined as the reduction of serotypes included in the vaccines and the rise of non-vaccine serotypes. This phenomenon has been widely described<sup>17,28–30</sup> and in Australia, was particularly evident in children aged less than 5 years and in non-Indigenous adults.

Penicillin and ceftriaxone/cefotaxime are the first and second line antibiotics recommended for use in Australia because of high levels of reported resistance to macrolides, especially erythromycin (17.6%).<sup>31</sup> The proportion of IPD cases with reduced susceptibility to penicillin did not change between 2006 and 2009 (10–11% in each year), but in 2010 the overall rate of resistance increased to 16% with resistance most common in serotypes 19A and 19F.

Post-immunisation surveillance in Australia is essential to monitor trends in IPD, to inform future control strategies, including the targeting of existing and new vaccines and the best options for antibiotic treatment. The Australian Government through the National IPD Laboratory Surveillance Project, provides funding to support the serotyping of all *S. pneumoniae* isolates causing invasive disease.

## Acknowledgements

Current EIPDSWG members are (in alphabetical order): David Coleman, Heather Cook (Secretariat), Rachel de Kluiver, Lucinda Franklin, Carolien Giele, Robin Gilmour, Vicki Krause (Chair), Rob Menzies, Sue Reid, Stacey

Rowe, Vitali Sintchenko, Helen Smith, Cindy Toms, Hannah Vogt and Angela Wakefield. The EIPDSWG would like to thank past members for their input to improvements in data quality and reporting.

We would also like to thank public health officers involved in the collection of surveillance data; state and territory public health communicable disease surveillance units; and the public and private laboratories that support pneumococcal laboratory surveillance.

## Author details

Christina Bareja<sup>1</sup>  
Cindy Toms<sup>1</sup>  
Kerryn Lodo<sup>2</sup>  
Rachel de Kluiver<sup>1</sup>

1. Vaccine Preventable Diseases Surveillance Section, Department of Health, Canberra, Australian Capital Territory
2. Communicable Diseases Prevention Unit, Department of Health and Human Services, Hobart, Tasmania.

Corresponding author: Dr Rachel de Kluiver, Vaccine Preventable Diseases Surveillance Section, Office of Health Protection, Australian Government Department of Health, GPO Box 9848, MDP 14, CANBERRA, ACT 2601. Telephone: +61 2 6289 1463. Facsimile: +61 2 6289 2600. Email: Rachel.de.kluiver@health.gov.au

## References

1. Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2010;59(RR-11):1–18.
2. Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, et al. Bacterial meningitis in the United States, 1998–2007. *N Engl J Med* 2011;364(21):2016–2025.
3. Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine Preventable Diseases in Australia, 2005 to 2007. *Commun Dis Intell* 2010;34(Suppl):S1–S172.
4. Australian Technical Advisory Group on Immunisation. *The Australian Immunisation Handbook*. 10th edn. Canberra, Australia: National Health and Medical Research Council and the Department of Health and Ageing; 2013.
5. Roche P, Krause V, Andrews R, Carter L, Coleman D, Cook H, et al. Invasive pneumococcal disease in Australia, 2002. *Commun Dis Intell* 2003;27(2):466–477.
6. Roche P, Krause V, Bartlett M, Coleman D, Cook H, Counahan M, et al. Invasive pneumococcal disease in Australia, 2003. *Commun Dis Intell* 2004;28(4):441–454.
7. Roche P, Krause V, Bartlett B, Coleman D, Cook H, Davis C, et al. Invasive pneumococcal disease in Australia, 2004. *Commun Dis Intell* 2006;30(1):80–92.

8. Roche P, Krause V, Cook H. Invasive pneumococcal disease in Australia, 2005. *Commun Dis Intell* 2007;31(1):86–100.
9. Roche P, Krause V, Cook H, Bartlett M, Coleman D, Davis C, et al. Invasive pneumococcal disease in Australia, 2006. *Commun Dis Intell* 2008;32(1):18–30.
10. Barry C, Krause VL, Cook HM, Menzies RI. Invasive pneumococcal disease in Australia 2007 and 2008. *Commun Dis Intell* 2012;36(2):E151–E165.
11. National Health Security Act, 2007. Accessed on November 2009. Available from: <http://www.comlaw.gov.au/Details/C2007A00174>
12. Communicable Diseases Network Australia. Surveillance Case Definitions for the Australian National Notifiable Diseases Surveillance System. 2004. Accessed on 25 June 2012. Available from: [http://www.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedefinitions.htm/\\$File/casedef-V4.pdf](http://www.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedefinitions.htm/$File/casedef-V4.pdf)
13. Australian Bureau of Statistics. 3101.0 – Australian Demographic Statistics, Jun 2013. Australian Bureau of Statistics; 2013.
14. Communicable Diseases Network Australia. Australian national notifiable diseases case definitions—Pneumococcal disease (invasive) case definition. 2004. Accessed on 27 March 2010. Available from: [http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd\\_pnuemo.htm](http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_pnuemo.htm)
15. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Significant events in pneumococcal vaccination practice in Australia. 2013. Accessed on 21 January 2014. Available from: <http://www.ncirs.edu.au/immunisation/history/Pneumococcal-history-December-2013.pdf>
16. Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistances in *Streptococcus pneumoniae* in Australia. *Med J Aust* 1999;170(4):152–155.
17. Miller E, Andrews N, Waight P, Slack M, George R. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. *Lancet Infect Dis* 2011;11(10):760–768.
18. Pilishvili T, Lexau C, Farley M, Hadler J, Harrison L, Bennett N, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine *J Infect Dis* 2010;201(1):32–41.
19. Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. *J Infect Dis* 2009;199(3):320–325.
20. Cooper D, Yu X, Sidhu M, Nahm MH, Ferstein P, Jansen KU. The 13-valent pneumococcal vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to *Streptococcus pneumoniae* serotypes 6C and 7A. *Vaccine* 2011;29(41):7207–7211.
21. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. *J Infect Dis* 2008;198(12):1818–1822.
22. Lynch JP 3rd, Zhanell GG. *Streptococcus pneumoniae*: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. *Curr Opin Pulm Med* 2010;16(3):217–225.
23. Hsieh YC, Lin TL, Chang KY, Huang YC, Chen CJ, Lin TY, et al. Expansion and evolution of *Streptococcus pneumoniae* serotype 19A ST320 clone as compared to its ancestral clone, Taiwan19F-14 (ST236). *J Infect Dis* 2013;208(2):203–210.
24. Ricketson LJ, Vanderkooi OG, Wood ML, Leal J, Kellner JD. Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta. *Can J Infect Dis Med Microbiol* 2014;25(2):e71–e75.
25. Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K. High incidence of septic shock caused by *Streptococcus pneumoniae* serotype 3—a retrospective epidemiological study. *BMC Infect Dis* 2013;13:492.
26. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant *Streptococcus pneumoniae* serotype 19A clones that cause acute otitis media in an unvaccinated population. *J Infect Dis* 2009;199(6):776–785.
27. Reinert RR. The antimicrobial resistance profile of *Streptococcus pneumoniae*. *Clin Microbiol Infect* 2009;15(Suppl. 3):7–11.
28. Hanquet G, Kissling E, Fenoll A, George R, Lepoutre A, Lernout T, et al. Pneumococcal serotypes in children in 4 European countries. *Emerg Infect Dis* 2010;16(9):1428–1439.
29. Dagan R. Serotype replacement in perspective. *Vaccine* 2009;27(Suppl 3):C22–C24.
30. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. *Lancet* 2011;378(9807):1962–1973.
31. European Centre for Disease Prevention and Control. Surveillance of invasive pneumococcal disease in Europe, 2010. Stockholm; 2012.